Welcome to the New SEngine Precision Medicine Newsletter

We look forward to updating you quarterly on our progress as we work together to fulfill our vision of a future when every cancer patient receives personalized, effective and less-toxic treatment.

Pulitzer Prize Winner to Lead Scientific Advisory Board
We're very pleased to announce that Siddhartha Mukherjee, MD, PhD, has joined the SEngine Precision Medicine Scientific Advisory Board. Dr. Mukherjee is the Pulitzer Prize-winning author of The Emperor of All Maladies: A Biography of Cancer and is one of our nation’s eminent thought leaders on cancer research. He’s an extraordinary addition to our growing team and we are proud he shares our vision and is joining our effort. Learn more here.

The Puget Sound Business Journal recently featured SEngine Precision Medicine CEO Dr. Carla Grandori in a story available online and in the weekly newspaper.

Dr. Grandori also recently accepted invitations to share the SEngine Precision Medicine story, unique market advantages, and leading-edge precision oncology technology by presenting during these upcoming conferences:

Follow SEngine Precision Medicine on Twitter and LinkedIn to receive the latest news, including an upcoming TV news story to be aired on the NBC affiliate in Seattle in the coming weeks.

Dr. Lee Hartwell Joins Board of Directors

We closed 2018 with a wonderful celebration to welcome Nobel laureate and former Fred Hutch President Dr. Lee Hartwell to the SEngine Board of Directors. We are honored to have such a prominent scientist in the cancer field endorse SEngine's approach as the path that “I would take if I had cancer.” His insights and leadership will be invaluable. Learn more in this news release.

New Funding Fuels
Growth Phase
The SEngine Board of Directors also welcomes Elliott Burkland. Elliott represents the lead investor group in SEngine’s ongoing Series A round which, when combined with earlier financings, has raised more than $8.2MM to date. The new funds are helping to launch SEngine’s current growth phase; we’ve secured additional lab space and will be growing our team to 10 full-time and two part-time employees. Among other new positions, we look forward to hiring a full-time medical director in the near future.
Planning for Growth in Asia
SEngine is making great progress in establishing a subsidiary company to bring the PARIS® Test to Chinese cancer patients. In December, the SEngine management team flew to Hong Kong to meet with leading business and government officials there to promote new business activities in Shandong Province. We also held a second meeting with BGI at the China National Gene Bank in Shenzhen (mainland China) to establish a partnership whereby BGI would provide DNA sequencing support. More to come on this soon.
New Contracts Bring Revenue, Crucial Data
Following a major effort to establish partnerships and secure contracts that align with our win-win model, SEngine has already finalized three new contracts that have generated revenue equal to ~1/3 of overall expenses this year. By providing services to pharmaceutical and cancer research organizations through our "rent a well on a tray" model, we’ve been able to offer the PARIS Test to patients at much lower costs while gathering crucial data on our own drug candidates. 
Advances Toward New Drug Development 
In November, we received a series of candidate molecules against our two leading targets. We are now in talks with medicinal chemists to help advance these molecules as well as other tool compounds with already proven results in organoids, to prepare clinical candidates. Through the work of Goldie Lui, a SEngine-sponsored post doc in Chris Kemp's Lab at the Hutch, a recent confirmation of the leading candidate targets has been obtained in ovarian cancer using CRISPR technology. This piece of data together with the organoids results will be crucial for future licensing.
CEO's Closing Thoughts
These are just a few of the highlights of what's already promising to be our best year yet here at SEngine Precision Medicine. I welcome the opportunity to connect with you personally to share more about what's in store for 2019 and beyond. Feel free to email me or find me on LinkedIn.

Thank you for your support and cheers to a wonderful and successful year ahead!

Carla Grandori, MD, PhD
CEO & Co-Founder
If you haven't already subscribed to receive our newsletters, you can do so here. Click below to share this newsletter with a friend or colleague.
Forward to a Friend
Copyright © 2019 SEngine Precision Medicine, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp